Kidney transplant patients may get new protection from dapagliflozin
NCT ID NCT06165601
First seen Apr 14, 2026 · Last updated Apr 30, 2026 · Updated 3 times
Summary
This study looked at whether dapagliflozin, a diabetes drug, can reduce protein in the urine (proteinuria) of kidney transplant patients with chronic kidney disease. Researchers followed 55 patients for 6 months to see if the drug lowered protein levels and protected kidney function. The goal was to find a new way to slow kidney disease in transplant recipients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Montpellier
Montpellier, 34295, France
Conditions
Explore the condition pages connected to this study.